Use of tivozanib to treat subjects with refractory cancer
US11504365B2 · kind B2 · utility
0Cited by
4References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 14, 2022 |
| Grant date | Nov 22, 2022 |
| Priority date | — |
| Expiry date | Apr 14, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/48
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a method of treating cancer, e.g., refractory cancer, with tivozanib. The methods disclosed include, for example, administering tivozanib as a second or third-line therapy to subjects suffering from refractory advanced renal cell carcinoma where traditional therapies as well as more recent targeted and immune-oncology therapies have not adequately treated the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.